MedTrace Logo

Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria

NCT01659515 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-01-02

No results posted yet for this study

Summary

Arbekacin for the use of infection caused by multidrug-resistant organisms

Conditions

  • Infection Due to Resistant Organism

Interventions

DRUG

Arbekacin Sulfate

Intravenous arbekacin in a total daily dose of 5-7 mg/kg

Sponsors & Collaborators

  • Meiji Seika Pharma Co., Ltd.

    collaborator INDUSTRY

  • Uniformed Services University of the Health Sciences

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Michael Zapor, MD, PhD · Walter Reed Army Institute of Research (WRAIR)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659515 on ClinicalTrials.gov